Sat, Oct 25, 2014, 4:10 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Antares Pharma Inc. Message Board

  • stockwaun stockwaun Mar 21, 2013 3:24 PM Flag

    NewsFlash! Pfizer AIMS at... (STRONG BUY)

    Pfizer is aiming at --

    1. NestraGel - that's right! Check the patent update. Pfizer is quietly preparing to take over this. (L-daug, check this out and you'll understand why.)

    2. Advil Gel - known (no longer a secret)

    3. Injector line

    Mr. Matusow's article is correct, but he's leaving out the NestraGel link. It's key to the story. The buy-out will be above $10 "if" the market drives the pps higher; otherwise lower as Mr. Matusow's explains.

    STRONG BUY

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Little retailers need to 'lock and load' because the BIG BOYS aren't going to be able to contain Pfizer from hiding behind its accumulators.

      ... That's right... Pfizer's is flying below the radar screen (Well... they were...)

      Sentiment: Strong Buy

    • Where is the new article by SMatusow? I haven't seen anything today, there is another article today on SA but not by Scott?

      Sentiment: Strong Buy

      • 2 Replies to jrdelane
      • Found it, article title starts with "Obaghi Medical Products Acquired" also mentions theory of Pfizer buyout of ATRS, which Wotton says is "not for sale."

        Sentiment: Strong Buy

      • Mr. Matusow is a genius. Not only did he blurb a SA article today, he tipped all of us a year ago when he wrote: "Being a gel, Nestragel would not face the type of issue faced above. I strongly feel Pfizer may be the big player for Nestragel, and that we can expect news on this very soon. I also feel Pfizer will buy-out Antares at some point within the next year."

        Pfizer sent Mr. Howarth (Scott caught him on that "insider" comment -- Geez, nobody seems to have caught what Scott tipped today) to Antares not only for Advil Gel, but for NestraGel. That is what Pfizer is after. Study Pfizer and you will understand. The injector addicts here won't understand, just as they live in denial about the company maintaining a 'gel' office in Europe (because Antares does).

        This is BIGGER THAN BIG. I just think the buy-out estimate could be plus $10 IF THIS NEWS REACHES THE RIGHT EARS (BLINK BLINK BLINK - CONSORTIUM! CONSORTIUM!)

        Expect the PPS to go UP UP UP!!! STRONG BUY IN AFTER HOURS

        Sentiment: Strong Buy

    • Which consortium? the one that was busted mid January?

      • 1 Reply to nthnsh
      • HERE'S WHAT YOU 'NEED TO KNOW' - PFIZER WILL BUY ANTARES FOR NESTRAGEL (and Advil Gel)---

        Raptor expert Mr. Matusow wrote over a year ago: "Being a gel, Nestragel would not face the type of issue faced above. I strongly feel Pfizer may be the big player for Nestragel, and that we can expect news on this very soon. I also feel Pfizer will buy-out Antares at some point within the next year." ANTARES: GOOD NEWS, NESTRAGEL NEXT

        ---

        His observation has not gone unnoticed. So many are so focused on the injector line, they seem to miss that Antares maintains its European office for (a) Advil Gel, and (b) the true secret -- NestraGel. The buyer of Antares' NestraGel is among us and it's Pfizer.

        ---
        The Consortium is watching. Seeing how the Consortium knows the value of NestraGel to a company like Pfizer, that Advil Gel will seem like small peanuts. (Like we've said: check the recent patents. NESTRAGEL IS VERY MUCH ALIVE AND WELL!!!) Thanks Mr. Matusow!!!! Yer awesome!!!

        STRONG BUY

        Sentiment: Strong Buy

    • Maybe you should write an SA article about it...
      Oh...wait...forgot... you can't.

 
ATRS
2.03+0.02(+1.00%)Oct 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.